For patients seeking dual-compound therapy, GLP-Squared injection begins at $289/mo (or $249/mo on the 3-month plan)
View Source PUBMED CENTRAL Triple Agonism Based Therapies for Obesity 2025 View Source PUBMED CENTRAL Retatrutide A Game Changer in Obesity Pharmacotherapy 2025 View Source PUBMED CENTRAL Efficacy and safety of retatrutide for obesity treatment: a systematic review and meta-analysis 2025 View Source ELI LILLY TRIUMPH-4 Phase 3 Trial Results 2025 View Source NATURE CELL DISCOVERY Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide 2024DOI: 10.1038/s41421-024-00700-0 View Source PUBCHEM DATABASE Retatrutide Compound Information View Source CLINICALTRIALS.GOV Retatrutide (LY3437943) Clinical Trials Registry View Source For Research Use Only Products are intended solely for laboratory and scientific research purposes
And it was amazing
Significant barriers still exist despite established safety profiles, such as high costs that restrict access worldwide, a lack of predictive biomarkers for treatment response, a lack of knowledge about the mechanistics of gut microbiota interactions, and an incomplete understanding of long-term safety, particularly with regard to thyroid and pancreatic effects
There is no need to aspirate (pull back on the plunger) when using pen injectors
When fiber reaches the colon, beneficial gut bacteria ferment it into short-chain fatty acids (SCFAs), which stimulate the release of GLP-1